Eleven Biotherapeutics Prices Initial Public Offering

Eleven Biotherapeutics Prices Initial Public Offering

February 6, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Eleven.

Tetraphase Pharmaceuticals Names Craig Thompson Chief Operating Officer

Tetraphase Pharmaceuticals Names Craig Thompson Chief Operating Officer

February 4, 2014

Brings broad experience in successful antibiotic development and commercialization

T2 Biosystems Awarded Top Honor as ‘Most Promising Company’ at Personalized Medicine World Conference 2014

T2 Biosystems Awarded Top Honor as ‘Most Promising Company’ at Personalized Medicine World Conference 2014

January 30, 2014

— T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced that it has been awarded top honor as the “Most Promising Company” at the 2014 Personalized Medicine World Conference held in Mountain View, CA, January 27-28. T2 Biosystems was chosen from a group of 22 competitors in recognition of its strong business model and team, as well as its innovative T2MR technology.

Quanterix Awarded Grant from GE and the NFL’s Head Health Challenge

Quanterix Awarded Grant from GE and the NFL’s Head Health Challenge

January 23, 2014

Lexington, Mass. – January 23, 2014 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that they have been selected as a winner of the GE and NFL Head Health Challenge from more than 400 entries across 27 countries by a panel of leading healthcare experts in brain research, imaging technologies and advocates for the advancement of brain research.

Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer

Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer

January 23, 2014

LEXINGTON, MA – Concert Pharmaceuticals, Inc. today announced the appointment of Ryan Daws as Chief Financial Officer. Mr. Daws brings to Concert more than 15 years of capital markets and financial advisory experience in the biotechnology and healthcare industry.

“Ryan has a strong track record leading a variety of financings and strategic transactions in the healthcare industry,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “He adds depth to Concert’s management team as we progress our drug development pipeline and grow the company.”

Renewable Energy Group Enters Industrial Biotech with Acquisition of LS9

Renewable Energy Group Enters Industrial Biotech with Acquisition of LS9

January 22, 2014

Expansion Provides REG with Renewable Chemicals Platform

(AMES, IA) January 22, 2014— Renewable Energy Group, Inc.® (NASDAQ: REGI) today announced it has acquired leading renewable chemical technology developer LS9, Inc. for a purchase price of up to $61.5 million, consisting of up front and earnout payments, in stock and cash. Most of the LS9 team, including the entire R&D leadership group, will join the newly named REG Life Sciences, LLC, which will operate out of LS9’s headquarters in South San Francisco, CA.

Oasys Water Expands to Support Commercialization and Manufacturing of Industry-Pioneering Forward Osmosis Systems

Oasys Water Expands to Support Commercialization and Manufacturing of Industry-Pioneering Forward Osmosis Systems

January 15, 2014

 Water treatment and desalination innovator sets the stage for continued growth in 2014

Moderna Launches Onkaido Therapeutics to Focus on the Development of mRNA Therapeutics™ in Oncology with $20 Million Capital Commitment

Moderna Launches Onkaido Therapeutics to Focus on the Development of mRNA Therapeutics™ in Oncology with $20 Million Capital Commitment

January 14, 2014

CAMBRIDGE, Mass.Jan.

Seres Health Announces Interim Clinical Data for SER-109 in Recurrent C. difficile

Seres Health Announces Interim Clinical Data for SER-109 in Recurrent C. difficile

January 13, 2014

Clinical efficacy observed in first 10 patients

Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics(TM) for Rare Diseases

Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics(TM) for Rare Diseases

January 13, 2014

CHESHIRE, Conn. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Moderna Therapeutics today announced an exclusive strategic agreement for the discovery and development of messenger RNA Therapeutics(TM) to treat rare diseases. Alexion is a global leader in the development and commercialization of breakthrough therapies for patients with severe and life-threatening rare diseases. Moderna is a pioneer in developing messenger RNA (mRNA) Therapeutics(TM), a highly innovative treatment modality to enable the in vivo production of therapeutic proteins.